Navigation Links
Newly approved ocular safety methods reduce animal testing
Date:6/23/2008

Federal regulatory agencies have accepted recommendations of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) for two methods that can reduce live animal use for ocular safety testing, the committee announced today. ICCVAM is a permanent interagency committee composed of representatives from 15 federal regulatory and research agencies, including the National Institutes of Health (NIH) that use, generate or disseminate toxicology testing information.

The two alternative test methods, the bovine corneal opacity and permeability (BCOP) assay and the isolated chicken eye (ICE) assay, do not involve the use of live animals. These are the first scientifically valid alternative methods to gain regulatory acceptance for ocular safety testing.

The Consumer Product Safety Commission (CPSC), the Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA) concurred with the ICCVAM recommendations for the BCOP and ICE tests. CPSC will now accept these tests instead of the conventional ocular toxicity test for the purpose of classification for labeling under the Federal Hazardous Substance Act (15 U.S.C. 1261-1278).

"Based on an extensive database of product test results, the use of these two alternative test methods will likely reduce the use of live animals for eye safety testing by 10 percent or more," stated William Stokes, D.V.M., the executive director of ICCVAM and director of the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods NICEATM). "More importantly, the use of these tests will eliminate the testing in animals of most substances likely to cause the most severe pain and discomfort."

If a positive response is obtained using either of the two new approved alternative methods, the product can be labeled as causing irreversible or severe eye damage and no live animal testing will be required. If the response is negative, the product is then tested in an animal to confirm that it does not cause severe or irreversible damage.

The NIH and other federal agencies are committed to the welfare of animals used in research. All animals used in federally funded research are protected by laws, regulations and policies to ensure they are used in the smallest number possible and with the greatest commitment to their comfort. ICCVAM is working to promote the development and validation of alternative test methods. Alternative test methods are those that accomplish one or more of the 3Rs of reducing the number of animals used in testing, or refining procedures so animals experience less pain and distress, or replacing animals with non-animal systems.

Marilyn Wind, Ph.D., chair of ICCVAM and principal ICCVAM representative for the CPSC said, "The use of these alternative methods will help reduce animal use while ensuring the proper identification and hazard labeling for substances that may cause severe or permanent eye damage."

Before certain new products such as drugs and pesticides can be marketed in the United States, they must be tested for their potential to adversely affect the health of consumers. Currently, the FDA, the CPSC and the EPA require that these and other products such as cosmetics, shampoos, detergents and household chemical products be labeled with information on hazards for human health. Tests that use animals are among the tests used by these federal agencies to evaluate potential damage to the eye that may result from exposure to these products. ICCVAM conducted a comprehensive scientific review of four alternative test methods and concluded that the BCOP and ICE methods can be useful for identifying products that may cause permanent or severe damage to an exposed eye. ICCVAM's evaluation report and recommendations were forwarded to federal agencies for their consideration in October 2007.

The ICCVAM Test Method Evaluation Report: In Vitro Ocular Toxicity Test Methods for Identifying Severe Irritants and Corrosives (NIH Publication 06-4511) contains the ICCVAM recommendations for these two alternative eye test methods and how results can be used to determine appropriate warning labels and special packaging requirements. The report also includes proposals for new studies that might further increase the usefulness of alternative test methods for detecting products that cause severe eye damage.

ICCVAM's recommendations were made after consideration of public comments and a report from an independent scientific peer review panel. The full report is available at the ICCVAM-NICEATM Web site (http://iccvam.niehs.nih.gov).

To have the greatest impact on reducing animal use, ICCVAM will seek adoption of these test methods internationally by the Organization of Economic Cooperation and Development so they can also be used in the other 29 OECD member countries, which include Japan and most countries in the European Union. There is considerable interest in these methods in Europe due to the impending 2009 ban by the EU on the use of animals for testing cosmetic ingredients and the EU chemicals legislation, REACH (Registration, Evaluation, Authorisation and Restriction of Chemical substances), which may require testing of thousands of existing chemicals.

ICCVAM is also evaluating several other non-animal methods that are expected to further reduce animal use for ocular testing including a proposed non-animal testing strategy for specific types of anti microbial products. The overall goal is an integrated testing strategy using several non-animal tests that can accurately predict whether chemicals or products have the potential to damage the eye.


'/>"/>

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Related medicine news :

1. Worlds Leading Health Experts Urge Countries to Use Newly Released Data to Prevent the Death of Millions of Children Due to Rotavirus
2. IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE)
3. Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohns Patients
4. Susan Byrne joins GHG Grey Healthcare Group as EVP, Strategy and Business Development, Europe, a Newly-Created Position
5. Newly Launched Regence Foundation to Help Transform Health Care and Influence the Nationwide Health Care Debate
6. Newly diagnosed breast cancer patients benefit from use of USFNA of lymph nodes
7. WellPoints Health Plans to Cover Newly Approved Cancer Treatment
8. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
9. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
10. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
11. Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology: